Year |
Citation |
Score |
2020 |
Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, Worden F, Brose M, Patel J, Leboulleux S, Godbert Y, Barlesi F, Morris JC, Owonikoko TK, Tan DSW, ... ... Lakhani N, et al. Efficacy of Selpercatinib in -Altered Thyroid Cancers. The New England Journal of Medicine. 383: 825-835. PMID 32846061 DOI: 10.1056/Nejmoa2005651 |
0.304 |
|
2020 |
Lakhani NJ, Patnaik A, Liao JB, Moroney JW, Miller DS, Fleming GF, Axt M, Wang YV, Agoram B, Volkmer J, Maute R, Schroeder A, Chico I, Chao M, Takimoto CH, et al. A phase Ib study of the anti-CD47 antibody magrolimab with the PD-L1 inhibitor avelumab (A) in solid tumor (ST) and ovarian cancer (OC) patients. Journal of Clinical Oncology. 38: 18-18. DOI: 10.1200/Jco.2020.38.5_Suppl.18 |
0.384 |
|
2020 |
Fisher GA, Lakhani NJ, Eng C, Hecht JR, Bendell JC, Philip PA, O'Dwyer PJ, Johnson B, Kardosh A, Ippolito TM, Wang YV, Agoram B, Volkmer J, Maute R, Chico I, et al. A phase Ib/II study of the anti-CD47 antibody magrolimab with cetuximab in solid tumor and colorectal cancer patients. Journal of Clinical Oncology. 38: 114-114. DOI: 10.1200/Jco.2020.38.4_Suppl.114 |
0.392 |
|
2020 |
Magid Diefenbach CS, Cohen JB, Harb WA, Ansell SM, Nastoupil LJ, Abramson JS, Lakhani NJ, Schreeder MT, Sher T, Patel-Donnelly D, Aboulafia DM, Fuchs CA, Nix D, Landrette S, Graham PS, et al. Results of a completed phase I study of LAM-002 (apilimod dimesylate), a first-in-class phosphatidylinositol-3-phosphate 5 kinase (PIKfyve) inhibitor, administered as monotherapy or with rituximab or atezolizumab to patients with previously treated follicular lymphoma or other B-cell cancers. Journal of Clinical Oncology. 38: 8017-8017. DOI: 10.1200/Jco.2020.38.15_Suppl.8017 |
0.414 |
|
2020 |
Lakhani NJ, Rasco DW, Zeng Q, Tang Y, Liang Z, Wang H, Lu M, Chen J, Fu L, Wang C, Yang D, Zhai Y. First-in-human study of palcitoclax (APG-1252), a novel dual Bcl-2/Bcl-xL inhibitor, demonstrated advantages in platelet safety while maintaining anticancer effect in U.S. patients with metastatic solid tumors. Journal of Clinical Oncology. 38: 3509-3509. DOI: 10.1200/Jco.2020.38.15_Suppl.3509 |
0.353 |
|
2020 |
Rasco DW, Lakhani NJ, Tang Y, Wang H, Ji J, Chen J, Liang Z, Amaya A, Yang D, Zhai Y. Phase Ib study of a novel bivalent IAP antagonist APG-1387 in combination of pembrolizumab for patients with advanced solid tumors. Journal of Clinical Oncology. 38: 3508-3508. DOI: 10.1200/Jco.2020.38.15_Suppl.3508 |
0.41 |
|
2020 |
Johnson ML, El-Khoueiry AB, Hafez N, Lakhani NJ, Mamdani H, Ahnert JR, Sanborn RE, Ho T, Li R, Waldes J, Spira AI. CX-2029, a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from a first-in-human study (PROCLAIM-CX-2029) in patients (Pts) with advanced cancer. Journal of Clinical Oncology. 38: 3502-3502. DOI: 10.1200/Jco.2020.38.15_Suppl.3502 |
0.338 |
|
2020 |
Chow LQM, Gainor JF, Lakhani NJ, Lee KW, Chung HC, Lee J, LoRusso P, Bang Y, Hodi FS, Santana-Davila R, Fanning P, Squifflet P, Jin F, Wan H, Kuo T, et al. A phase I study of ALX148, a CD47 blocker, in combination with standard anticancer antibodies and chemotherapy regimens in patients with advanced malignancy. Journal of Clinical Oncology. 38: 3056-3056. DOI: 10.1200/Jco.2020.38.15_Suppl.3056 |
0.358 |
|
2020 |
Schram A, Borazanci E, Brana I, Villar MV, Garralda E, Spreafico A, Oliva M, Lakhani N, Wasserman R, Hoffmann K, Hallett R, Anido J, Maetzel D, Giblin P, Moran E, et al. Abstract CT147: Phase 1 dose escalation of MSC-1, a humanized anti-LIF monoclonal antibody, in patients with advanced solid tumors Tumor Biology. DOI: 10.1158/1538-7445.Am2020-Ct147 |
0.4 |
|
2020 |
Yap T, Araujo D, Wood D, Denis J, Gruosso T, Tremblay G, O’Connor-McCourt M, Ghosh R, Sinclair S, Nadler P, Siu L, Lakhani N. P856 AVID200, first-in-class TGF-beta1 and beta3 selective inhibitor: results of a phase 1 monotherapy dose escalation study in solid tumors and evidence of target engagement in patients Journal For Immunotherapy of Cancer. 8. DOI: 10.1136/Lba2019.10 |
0.356 |
|
2019 |
Sikic BI, Lakhani N, Patnaik A, Shah SA, Chandana SR, Rasco D, Colevas AD, O'Rourke T, Narayanan S, Papadopoulos K, Fisher GA, Villalobos V, Prohaska SS, Howard M, Beeram M, et al. First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1802018. PMID 30811285 DOI: 10.1200/Jco.18.02018 |
0.366 |
|
2019 |
Rasco DW, Lakhani NJ, Li Y, Men L, Wang H, Ji J, Tang Y, Liang Z, Amaya A, Estkowski K, Sun J, Huang Y, Yang D, Zhai Y. A phase I study of a novel MDM2 antagonist APG-115 in patients with advanced solid tumors. Journal of Clinical Oncology. 37: 3126-3126. DOI: 10.1200/Jco.2019.37.15_Suppl.3126 |
0.381 |
|
2019 |
Shahda S, Lakhani NJ, O'Neil B, Rasco DW, Wan J, Mosley AL, Liu H, Kelley MR, Messmann RA. A phase I study of the APE1 protein inhibitor APX3330 in patients with advanced solid tumors. Journal of Clinical Oncology. 37: 3097-3097. DOI: 10.1200/Jco.2019.37.15_Suppl.3097 |
0.472 |
|
2019 |
Chow LQM, Gainor JF, Lakhani NJ, Chung HC, Lee K, Lee J, LoRusso P, Bang Y, Hodi FS, Fanning P, Zhao Y, Jin F, Wan H, Pons J, Randolph S, et al. A phase I study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy. Journal of Clinical Oncology. 37: 2514-2514. DOI: 10.1200/Jco.2019.37.15_Suppl.2514 |
0.349 |
|
2019 |
Papadopoulos KP, Lakhani NJ, Johnson ML, Park H, Wang D, Yap TA, Dowlati A, Maki RG, Lynce F, Ulahannan SV, Kelly K, Sims TN, Bredlau A, Bramble D, Gonzalez Ortiz A, et al. First-in-human study of REGN3767 (R3767), a human LAG-3 monoclonal antibody (mAb), ± cemiplimab in patients (pts) with advanced malignancies. Journal of Clinical Oncology. 37: 2508-2508. DOI: 10.1200/Jco.2019.37.15_Suppl.2508 |
0.369 |
|
2019 |
Kim TM, Lakhani N, Gainor J, Kamdar M, Fanning P, Squifflet P, Jin F, Wan H, Pons J, Randolph SS, Kim WS. A Phase 1 Study of ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma Blood. 134: 1953-1953. DOI: 10.1182/Blood-2019-123219 |
0.331 |
|
2019 |
Lakhani N, Chandana S, Tolcher A, Cole Y, Rivas K, Sinclair S, Nadler PI, Wood DL, Papadopoulos KP. Abstract CT056: A Phase Ia/IIa trial of AVID100, an anti-EGFR antibody-drug conjugate Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct056 |
0.484 |
|
2019 |
Schram A, Spreafico A, Oliva M, Brana I, Garralda E, Lakhani N, Hoff DV, Borazanci E, Pandya N, Hoffman K, Hallett R, Giblin P, Anido J, Kelly A, Wasserman R, et al. Abstract CT014: Initial results from the Phase I study of MSC-1, a humanized anti-LIF monoclonal antibody, in patients with advanced solid tumors Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct014 |
0.483 |
|
2019 |
Tolcher AW, Sullivan RJ, Rasco DW, Eroglu Z, Lakhani N, Kessler D, Usansky H, Reddy S, Denis LJ, Janku F. Abstract PR09: Phase 1 clinical safety and efficacy of ASN007, a novel oral ERK1/2 inhibitor, in patients with RAS, RAF or MEK mutant advanced solid tumors Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-Pr09 |
0.458 |
|
2019 |
Kelley MR, Shahda S, Lakhani NJ, O'Neil B, Chu L, Anderson AK, Wan J, Mosley AL, Liu H, Messmann RA. Abstract PR01: A phase I study targeting the APE1/Ref-1 DNA repair-redox signaling protein with the APX3330 inhibitor Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-Pr01 |
0.472 |
|
2019 |
Melear J, Lakhani N, O'Shaughnessy JA, Wilks ST, Khan S, Chandana SR, Tolcher AW, Papadopoulos KP, Cole Y, Rivas K, Ghosh R, Sinclair S, Lutz R, Nadler PI, Wood DL, et al. Abstract A088: Novel anti-EGFR antibody-drug conjugate AVID100: A phase 2a trial in patients with EGFR-overexpressing advanced solid tumors Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-A088 |
0.438 |
|
2019 |
Borazanci E, Schram A, Brana I, Villar MV, Garralda E, Spreafico A, Oliva M, Lakhani N, Wasserman R, Hoffman K, Hallett R, Anido J, Giblin P, Pandya N, Kelly A, et al. Phase I dose escalation of MSC-1, a humanized anti-LIF monoclonal antibody, in patients (pts) with advanced solid tumours: Updated results Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz253.022 |
0.381 |
|
2019 |
Drilon A, Oxnard G, Wirth L, Besse B, Gautschi O, Tan SWD, Loong H, Bauer T, Kim YJ, Horiike A, Park K, Shah M, McCoach C, Bazhenova L, Seto T, ... ... Lakhani N, et al. PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.08.059 |
0.338 |
|
2018 |
Papadopoulos KP, Lakhani NJ, Johnson ML, Park H, Wang D, Yap TA, Moore KN, Sims TN, Emeremni C, Karasarides M, Kroog GS. A study of REGN3767, an anti-LAG-3 antibody, alone and in combination with cemiplimab (REGN2810), an anti-PD1 antibody, in advanced cancers. Journal of Clinical Oncology. 36: TPS3127-TPS3127. DOI: 10.1200/Jco.2018.36.15_Suppl.Tps3127 |
0.348 |
|
2018 |
Sachdev JC, Maitland ML, Sharma M, Moreno V, Boni V, Kummar S, Stringer-Reasor EM, Forero-Torres A, Lakhani NJ, Gibson B, Xuan D, Joh T, Powell EL, Jackson-Fisher A, Xin X(, et al. PF-06647020 (PF-7020), an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in patients (pts) with advanced solid tumors: Results of a phase I dose escalation and expansion study. Journal of Clinical Oncology. 36: 5565-5565. DOI: 10.1200/Jco.2018.36.15_Suppl.5565 |
0.402 |
|
2018 |
Lakhani NJ, LoRusso P, Hafez N, Krishnamurthy A, O'Rourke TJ, Kamdar MK, Fanning P, Zhao Y, Jin F, Wan H, Pons J, Randolph S, Messersmith WA. A phase 1 study of ALX148, a CD47 blocker, alone and in combination with established anticancer antibodies in patients with advanced malignancy and non-Hodgkin lymphoma. Journal of Clinical Oncology. 36: 3068-3068. DOI: 10.1200/Jco.2018.36.15_Suppl.3068 |
0.364 |
|
2018 |
Sikic BI, Lakhani NJ, Patnaik A, Shah S, Chandana SR, Rasco DW, Colevas AD, O'Rourke TJ, Papadopoulos KP, Fisher GA, Chao M, Agoram B, Chen JY, Huang J, Axt M, et al. A first-in-class, first-in-human phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of Hu5F9-G4, an anti-CD47 monoclonal antibody (mAb), in patients with advanced solid tumors. Journal of Clinical Oncology. 36: 3002-3002. DOI: 10.1200/Jco.2018.36.15_Suppl.3002 |
0.373 |
|
2018 |
Lakhani NJ, Rasco DW, Tolcher AW, Huang Y, Ji J, Wang H, Dong Q, Men L, O'Rourke TJ, Chandana SR, Amaya A, Cole Y, Kaiser B, Mays TA, Patnaik A, et al. A phase I study of novel dual Bcl-2/Bcl-xL inhibitor APG-1252 in patients with advanced small cell lung cancer (SCLC) or other solid tumor. Journal of Clinical Oncology. 36: 2594-2594. DOI: 10.1200/Jco.2018.36.15_Suppl.2594 |
0.401 |
|
2018 |
Xuan D, Xin X(, Gibson B, Joh T, Yin H, Garzone PD, Sachdev JC, Maitland ML, Sharma M, Moreno V, Calvo E, Kummar S, Stringer-Reasor EM, Lakhani NJ, Tolcher AW, et al. Clinical pharmacology assessment of PF-06647020 (PF-7020), an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in adult patients (pts) with advanced solid tumors. Journal of Clinical Oncology. 36: 2574-2574. DOI: 10.1200/Jco.2018.36.15_Suppl.2574 |
0.358 |
|
2018 |
Agoram B, Wang B, Sikic BI, Lakhani NJ, Patnaik A, Liu J, Secreto R, Chao M, Takimoto CH. Pharmacokinetics of Hu5F9-G4, a first-in-class anti-CD47 antibody, in patients with solid tumors and lymphomas. Journal of Clinical Oncology. 36: 2525-2525. DOI: 10.1200/Jco.2018.36.15_Suppl.2525 |
0.39 |
|
2018 |
Drilon AE, Subbiah V, Oxnard GR, Bauer TM, Velcheti V, Lakhani NJ, Besse B, Park K, Patel JD, Cabanillas ME, Johnson ML, Reckamp KL, Boni V, Loong HHF, Schlumberger M, et al. A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers. Journal of Clinical Oncology. 36: 102-102. DOI: 10.1200/Jco.2018.36.15_Suppl.102 |
0.368 |
|
2018 |
Rasco D, Lakhani N, Sullivan R, Mita M, Shah J, Usansky H, Reddy S, Rao NS, Toker S, Denis L, Flaherty K, Tolcher A. Abstract CT019: ASN003, a novel highly selective BRAF and PI3K dual inhibitor: Phase I PK/PD results in patients with advanced solid tumors Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Ct019 |
0.434 |
|
2018 |
Rasco D, Lakhani N, Sullivan R, Mita M, Shah J, Usansky H, Reddy S, Rao N, Denis LJ, Tolcher A, Flaherty K. Abstract B147: A phase 1 PK/PD study of ASN003, a novel, highly selective BRAF and PI3K dual inhibitor, in patients with advanced solid tumors Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-B147 |
0.444 |
|
2017 |
Rasco DW, Sullivan RJ, Lakhani NJ, Reddy S, Rao NS, Denis LJ, Tolcher AW, Flaherty K. ASN003, a highly selective BRAF and PI3K inhibitor: Preclinical and phase 1 clinical data in patients with advanced solid tumors. Journal of Clinical Oncology. 35: e14102-e14102. DOI: 10.1200/JCO.2017.35.15_SUPPL.E14102 |
0.316 |
|
2017 |
Tolcher AW, Su WC, Lakhani N, Gutheil J, Melink TJ, Chu Y, Chen Y, Chien D. Phase I dose escalation study of CVM-1118, a novel anti-vascular mimicry agent, in patients with advanced cancers. Journal of Clinical Oncology. 35: 2580-2580. DOI: 10.1200/Jco.2017.35.15_Suppl.2580 |
0.487 |
|
2017 |
Lakhani N, Tolcher AW, Rasco DW, Patnaik A, O'Rourke TJ, Schwartz BE, Abbadessa G, Kazakin J, Savage R, Wang Y, Chai F, Papadopoulos KP. Results of a phase Ib study of ARQ 092 in combination with carboplatin (C) plus paclitaxel (P), or with P in patients (pts) with solid tumors. Journal of Clinical Oncology. 35: 2524-2524. DOI: 10.1200/Jco.2017.35.15_Suppl.2524 |
0.371 |
|
2017 |
Topp MS, Borchmann P, Wagner-Johnston ND, Provencio M, Cordoba R, Papadopoulos K, Martín A, Grande C, Jagadeesh D, Lakhani N, Vos Sd, Mato AR, Brunnberg U, Scholl S, Pott C, et al. Safety and Preliminary Antitumor Activity of the Anti-PD-1 Monoclonal Antibody REGN2810 Alone or in Combination with REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with B-Lymphoid Malignancies Blood. 130: 1495-1495. DOI: 10.1182/Blood.V130.Suppl_1.1495.1495 |
0.354 |
|
2007 |
Lakhani NJ, Sparreboom A, Xu X, Veenstra TD, Venitz J, Dahut WL, Figg WD. Characterization of in vitro and in vivo metabolic pathways of the investigational anticancer agent, 2-methoxyestradiol. Journal of Pharmaceutical Sciences. 96: 1821-31. PMID 17252610 DOI: 10.1002/Jps.20837 |
0.36 |
|
2006 |
Lakhani N, Sparreboom A, Venitz J, Dahut WL, Figg WD. Plasma protein binding of the investigational anticancer agent 2-methoxyestradiol. Anti-Cancer Drugs. 17: 977-83. PMID 16940808 DOI: 10.1097/01.Cad.0000224447.08706.92 |
0.439 |
|
2006 |
Dahut WL, Lakhani NJ, Gulley JL, Arlen PM, Kohn EC, Kotz H, McNally D, Parr A, Nguyen D, Yang SX, Steinberg SM, Venitz J, Sparreboom A, Figg WD. Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biology & Therapy. 5: 22-7. PMID 16357512 DOI: 10.4161/Cbt.5.1.2349 |
0.541 |
|
2005 |
Lakhani NJ, Lepper ER, Sparreboom A, Dahut WL, Venitz J, Figg WD. Determination of 2-methoxyestradiol in human plasma, using liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry : Rcm. 19: 1176-82. PMID 15818726 DOI: 10.1002/Rcm.1902 |
0.342 |
|
2005 |
Lakhani NJ, Sparreboom A, Venitz J, Dahut W, Figg WD. Single oral dose pharmacokinetics (PK) and safety of 2-methoxyestradiol (2ME2) in patients with solid tumors Journal of Clinical Oncology. 23: 2071-2071. DOI: 10.1200/Jco.2005.23.16_Suppl.2071 |
0.498 |
|
2004 |
Lakhani NJ, Sparreboom A, Dahut WL, Venitz J, Figg WD. Determination of the antiangiogenesis agent 2-methoxyestradiol in human plasma by liquid chromatography with ultraviolet detection. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 806: 289-93. PMID 15171941 DOI: 10.1016/J.Jchromb.2004.03.046 |
0.405 |
|
2003 |
Lakhani NJ, Venitz J, Figg WD, Sparreboom A. Pharmacogenetics of estrogen metabolism and transport in relation to cancer. Current Drug Metabolism. 4: 505-13. PMID 14683478 DOI: 10.2174/1389200033489244 |
0.424 |
|
2003 |
Hamilton M, Dahut W, Brawley O, Davis P, Wells-Jones T, Kohler D, Duray P, Liewehr DJ, Lakhani N, Steinberg SM, Figg WD, Reed E. A phase I/II study of high-dose tamoxifen in combination with vinblastine in patients with androgen-independent prostate cancer. Acta Oncologica (Stockholm, Sweden). 42: 195-201. PMID 12852695 DOI: 10.1080/02841860310010718 |
0.498 |
|
2003 |
Fine HA, Wen PY, Maher EA, Viscosi E, Batchelor T, Lakhani N, Figg WD, Purow BW, Borkowf CB. Phase II Trial of Thalidomide and Carmustine for Patients With Recurrent High-Grade Gliomas Journal of Clinical Oncology. 21: 2299-2304. PMID 12805330 DOI: 10.1200/Jco.2003.08.045 |
0.534 |
|
2003 |
Horne MK, Figg WD, Arlen P, Gulley J, Parker C, Lakhani N, Parnes H, Dahut WL. Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer. Pharmacotherapy. 23: 315-8. PMID 12627929 DOI: 10.1592/Phco.23.3.315.32106 |
0.438 |
|
2003 |
Lakhani NJ, Sarkar MA, Venitz J, Figg WD. 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy. 23: 165-72. PMID 12587805 DOI: 10.1592/Phco.23.2.165.32088 |
0.52 |
|
2002 |
Macpherson GR, Ng SS, Lakhani NJ, Price DK, Venitz J, Figg WD. Antiangiogenesis therapeutic strategies in prostate cancer. Cancer Metastasis Reviews. 21: 93-106. PMID 12400998 DOI: 10.1007/0-306-48143-X_20 |
0.468 |
|
Show low-probability matches. |